To our knowledge, we have provided the first evidence indicating that PI3K activity is a requirement for akt gene expression and that by targeting PI3K, βGBP can therapeutically suppress akt gene expression and lead to death in tumour cells where the ErbB2 oncoprotein is overexpressed while causing no significant damage to mammary ductal cells. Here, AKT1 is linked to neoplasm.